^
Association details:
| Biomarker: | HLA-A2 positive + PMEL overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) + Kimmtrak (tebentafusp-tebn) (CD3 agonist, gp100 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
Published date:
05/26/2022
Excerpt:
Patients with HLA-A2+, pre-treated mCM received weekly tebe (IV) monotherapy in Arm 4a or in combination with dose escalation of durva and/or treme (IV) on day 15 of each cycle (Arms 1-3). Promising OS is seen in mCM similar to mUM, with both tumor types overexpressing gp100. In mCM relapsed or refractory to prior anti-PD1, tebe with anti–PD-L1 continues to demonstrate promising OS (1-yr, approx. 75%) compared to recent benchmarks (1-yr, approx. 55%).
DOI:
10.1200/JCO.2022.40.16_suppl.104
Trial ID:
